
|Articles|June 1, 2001
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Rx-to-OTC: Unwanted Attention
Author(s)Kevin Gopal
Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.
Advertisement
Articles in this issue
over 24 years ago
Industry Under Investigationover 24 years ago
Emotion - The New Brand Integratorover 24 years ago
For Love of the Gameover 24 years ago
Field of Dreamsover 24 years ago
Workshop: Access Optionsover 24 years ago
Emotion - The New Brand Integratorover 24 years ago
Emotion - Biotech Renaissance Manover 24 years ago
Relocation: Coming to Americaover 24 years ago
Stocks: Catching the Market Bluesover 24 years ago
Gathering LightNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5





